Last updated: 20 February 2024 at 4:45pm EST

Jama Pitman Net Worth




The estimated Net Worth of Jama Pitman is at least $1.94 Million dollars as of 15 February 2024. Ms Pitman owns over 2,267 units of Deciphera Pharmaceuticals Inc stock worth over $1,740,913 and over the last 3 years she sold DCPH stock worth over $195,068.

Ms Pitman DCPH stock SEC Form 4 insiders trading

Ms has made over 9 trades of the Deciphera Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 2,267 units of DCPH stock worth $35,411 on 15 February 2024.

The largest trade she's ever made was selling 2,267 units of Deciphera Pharmaceuticals Inc stock on 15 February 2024 worth over $35,411. On average, Ms trades about 1,219 units every 66 days since 2021. As of 15 February 2024 she still owns at least 68,031 units of Deciphera Pharmaceuticals Inc stock.

You can see the complete history of Ms Pitman stock trades at the bottom of the page.





Ms. Jama Pitman biography

Jama Pitman is the Sr. VP of Regulatory, Quality & Portfolio Management at Deciphera Pharmaceuticals Inc.



How old is Ms Pitman?

Ms Pitman is 42, she's been the Sr. VP of Regulatory and Quality & Portfolio Management of Deciphera Pharmaceuticals Inc since . There are 20 older and no younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.

What's Ms Pitman's mailing address?

Jama's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.

Insiders trading at Deciphera Pharmaceuticals Inc

Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar, and Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.



What does Deciphera Pharmaceuticals Inc do?

deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.



What does Deciphera Pharmaceuticals Inc's logo look like?

Deciphera Pharmaceuticals Inc logo

Complete history of Ms Pitman stock trades at Deciphera Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
15 Feb 2024 Jama Pitman
SVP and Chief Development Officer
Sale 2,267 $15.62 $35,411
15 Feb 2024
68,031
16 Jan 2024 Jama Pitman
SVP and Chief Development Officer
Sale 1,624 $14.47 $23,499
16 Jan 2024
50,573
12 Dec 2023 Jama Pitman
SVP and Chief Development Officer
Sale 1,662 $15.37 $25,545
12 Dec 2023
52,197
28 Oct 2023 Jama Pitman
SVP and Chief Development Officer
Sale 1,407 $12.02 $16,912
28 Oct 2023
48,283
16 Jun 2023 Jama Pitman
SVP and Chief Development Officer
Sale 1,238 $14.40 $17,827
16 Jun 2023
43,812
15 Feb 2023 Jama Pitman
SVP and Chief Development Officer
Sale 1,159 $15.10 $17,501
15 Feb 2023
45,050
17 Jan 2023 Jama Pitman
SVP and Chief Development Officer
Sale 1,603 $21.24 $34,048
17 Jan 2023
35,058
16 Jun 2022 Jama Pitman
SVP and Chief Development Officer
Sale 1,298 $10.75 $13,954
16 Jun 2022
36,661
16 Feb 2022 Jama Pitman
SVP and Chief Development Officer
Sale 1,146 $9.05 $10,371
16 Feb 2022
37,959


Deciphera Pharmaceuticals Inc executives and stock owners

Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: